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Abstract: Glucocorticoid hormones (GCs) released from the fetal/maternal glands during late
gestation are required for normal development of mammalian organs and tissues. Accordingly,
synthetic glucocorticoids have proven to be invaluable in perinatal medicine where they are widely
used to accelerate fetal lung maturation when there is risk of pre-term birth and to promote infant
survival. However, clinical and pre-clinical studies have demonstrated that inappropriate exposure
of the developing brain to elevated levels of GCs, either as a result of clinical over-use or after
stress-induced activation of the fetal/maternal adrenal cortex, is linked with significant effects
on brain structure, neurological function and behaviour in later life. In order to understand the
underlying neural processes, particular interest has focused on the midbrain dopaminergic systems,
which are critical regulators of normal adaptive behaviours, cognitive and sensorimotor functions.
Specifically, using a rodent model of GC exposure in late gestation (approximating human brain
development at late second/early third trimester), we demonstrated enduring effects on the shape
and volume of the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) (origins of
the mesocorticolimbic and nigrostriatal dopaminergic pathways) on the topographical organisation
and size of the dopaminergic neuronal populations and astrocytes within these nuclei and on
target innervation density and neurochemical markers of dopaminergic transmission (receptors,
transporters, basal and amphetamine-stimulated dopamine release at striatal and prefrontal cortical
sites) that impact on the adult brain. The effects of antenatal GC treatment (AGT) were both profound
and sexually-dimorphic, not only in terms of quantitative change but also qualitatively, with several
parameters affected in the opposite direction in males and females. Although such substantial
neurobiological changes might presage marked behavioural effects, in utero GC exposure had only
a modest or no effect, depending on sex, on a range of conditioned and unconditioned behaviours
known to depend on midbrain dopaminergic transmission. Collectively, these findings suggest
that apparent behavioural normality in certain tests, but not others, arises from AGT-induced
adaptations or compensatory mechanisms within the midbrain dopaminergic systems, which
preserve some, but not all functions. Furthermore, the capacities for molecular adaptations to early
environmental challenge are different, even opponent, in males and females, which may account
for their differential resilience or failure to perform adequately in behavioural tests. Behavioural
“normality” is thus achieved by the midbrain dopaminergic network operating outside its normal
Brain Sci. 2017, 7, 5; doi:10.3390/brainsci7010005 www.mdpi.com/journal/brainsci
Brain Sci. 2017, 7, 5 2 of 29
limits (in a state of allostasis), rendering it at greater risk to malfunction when challenged in later life.
Sex-specific neurobiological programming of midbrain dopaminergic systems may, therefore, have
psychopathological relevance for the sex bias commonly found in brain disorders associated with
these systems, and which have a neurodevelopmental component, including schizophrenia, ADHD
(attention/deficit hyperactivity disorders), autism, depression and substance abuse.
Keywords: dopaminergic neurones; astrocytes; midbrain; ventral tegmental area; substantia nigra
pars compacta; antenatal glucocorticoid treatment; developmental programming; sex dimorphisms
1. Introduction
Mental health problems are widely recognised as leading causes of illness and disability.
The World Health Organisation (WHO) reported that worldwide one in four adults will be affected
by mental and behavioural disorders during their lives. Mental health issues are also on the rise,
especially in children and young adults, in whom various types of mental illness have doubled over
the last decade, such that now one in five young people under the age of 18 are affected with conditions
that may remain with them into adulthood. In addition to improving treatments, the most recent
emphasis by global bodies, such as WHO, the United Nations, charities and governments, has been
on removing the stigma and discrimination attached to mental disorders, as well as addressing the
reluctance of those who suffer from these conditions to come forward for diagnosis and treatment.
However, scientific advances are also being made to understand the origins of mental illness, which
will be key for developing better therapeutic strategies and for realising the potential to reverse or
prevent these conditions. In addition to genetic make-up, we now know that environmental and
social factors and stressors interact to influence an individual’s susceptibility to becoming mentally
ill [1–3]. We also understand that mental illness is associated with changes in the structure, chemistry
and function of the brain; moreover, these changes are superimposed on innate differences in brain
anatomy, neurochemistry and function according to one’s sex, as defined by reproductive organs
(testes or ovaries) and sex chromosomes (XX in males, XY in females) [4,5]. These physiological and
structural brain differences are thought to underpin sex differences that are manifest in virtually
all aspects of neurological and psychological disorders, ranging from susceptibility, prevalence,
presentation and symptoms to disease progression, pathology and response to treatments. Collectively,
these observations lead to the conclusion that there is, indeed, a biological basis for mental health
conditions, as well as for the sex bias which characterises them, indicating that diagnostic, treatment
and preventative strategies should be differentially targeted inmen andwomen. Therefore, we urgently
need to understand how changes in the brain that lead to brain disorders are created.
A large body of evidence from human and animal research has established that perturbations in
the normal environment during early life, especially fetal life, programme changes in brain structure
and function and profoundly affect vulnerability to disease, including mental health problems, that
may emerge in childhood, adolescence or adulthood [3,6–9]. However, the precise neural substrate and
themechanismswhich link the early environment to the development of adult psychopathology remain
poorly characterised. In this review we shall focus on the midbrain dopaminergic systems as the neural
substrate and on exposure during prenatal life to inappropriately elevated levels of glucocorticoids
(GCs) as a mechanism which disrupts the normal developmental trajectories of these systems. After
summarising briefly the roles of the midbrain dopaminergic systems in health and disease, we shall
consider the evidence that these systems are highly sensitive to disturbances in the intrauterine
environment by a broad range of stressors, and that GCs, commonly released in response to all types of
stressors, are key factors responsible for early life programming in general, which differentially affect
male and female brains. We shall then focus on how the structure, neurochemistry and function of the
adult dopaminergic systems are altered in rodent male and female brains after brief antenatal treatment
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with GCs. Elucidating links between developmental exposure to GCs and dopaminergic malfunction in
adulthood could, therefore, contribute to our understanding of the aetiology of brain disorders which,
in most instances, differentially affect men and women. This may also have importance from a clinical
perspective in view of the association between childhood behavioural deficits with repeated courses of
synthetic GCs that are commonly prescribed to accelerate fetal lung function in the management of
women at risk of preterm delivery [10–12].
2. Midbrain Dopaminergic Systems
2.1. Function
The midbrain dopaminergic systems are critical for integrating mammalian behavioural responses
and adaptations to changes in the environment, thus enabling the individual to cope with what is
perceived as a threat or stress [13–16]. Sub-sets of neurons in the ventral tegmental area (VTA) give rise
to two major pathways: the mesolimbic dopaminergic (MLDA) pathway that innervates the ventral
striatum, especially the nucleus accumbens (NAc), to regulate the process controlling emotion, reward
and feeding, and the mesocortical dopaminergic (MCDA) pathway projecting to the prefrontal cortex,
involved in cognition. Neurons in the substantia nigra pars compacta (SNc) form the nigrostriatal
dopaminergic (NSDA) pathway innervating the dorsal striatum, which is central to sensorimotor
integration, and may also interact with the MLDA under certain circumstances [17]. These systems
form a highly responsive, stressor–sensitive circuitry. Stress or aversive events activate sub-sets of
VTA neurons to stimulate the process of learning and memory [18–26], thereby enabling the storage
and recall of appropriate coping behaviours when similar situations are encountered subsequently.
Stress-induced activation of the SNc neurons [20] contributes to altered locomotor activity that typically
accompanies stress, and their activation may ultimately also feed into the cognitive systems [17,27].
2.2. Malfunction, Neurobiological Programming and Sex Dimorphisms
2.2.1. Malfunction
While the majority of individuals, human or non-human, can cope well with stress, we know
that others cannot, and this failure of coping mechanisms is an established risk factor for developing
brain disorders [1,28–30]. Not surprisingly, therefore, malfunction of dopamine (DA)-dependent
stress-coping circuitry is a prevalent factor in psychopathology, contributing to disorders such as
schizophrenia [31], anxiety and depression [32], addictive behaviours [33,34] and attention/deficit
hyperactivity disorders (ADHD) [35,36] that primarily involve the VTA DA systems. To some extent,
this can be modelled experimentally, where exposure of rats to chronic stress also has consequences for
the VTA system. Unlike the positive coping response to acute stress in the MLDA/MCDA pathways,
tonic activity may be down-regulated after chronic stress [37], leading to reduced dopaminergic
transmission to the medial prefrontal cortex (mPFC) and deficiencies in working memory [38,39]. This
also has the consequence of increased DA release in the NAc, which is under inhibitory control from
the mesocortical system, leading to behavioural change [40]. Stress dysfunction involving the SNc may
further have a role in the aetiology of the pre-clinical, non-motor symptoms of Parkinson’s disease
(PD, such as depression), as well as the later progression of the motor symptoms, which characterise
the condition [41,42].
2.2.2. Neurobiological Programming
Although the aetiologies of the aforementioned conditions associated with dopaminergic
malfunction remain poorly understood, it is now well established that during critical stages of
development, especially fetal life, stress due to a host of different causes, can have detrimental effects on
the maturing brain, with implications for abnormal behaviours, emotional problems and the emergence
of neurological and neuropsychiatric conditions in later life [3,7–9,31,43–45]. Moreover, the midbrain
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dopaminergic systems appear to be central to this phenomenon. For example, it has been estimated
that, in addition to a genetic neurodevelopmental component, 20%–30% causation in schizophrenia
may be non-genetic and attributable to an adverse or sub-optimal intra-uterine environment arising
from stressors, including obstetric complications, exposure of the mother to natural disasters (such
as famine and malnutrition), death of a loved one, low socio-economic status and infections (such as
influenza) [46–50]. Perinatal/obstetric complications and prenatal stressors are also associated with
ADHD [51] and autism spectrum disorders [52]. Additionally, low birth weight (typically taken as a
marker of intra-uterine metabolic stress) and other stressors have been associated with an increased
risk for developing anxiety and depression [2,53,54]. An adverse intra-uterine environment may
also contribute to causing or predisposing the NSDA system to degenerate in PD [55]. Although
such epidemiological evidence is largely associative and not proof of cause and effect, animal models
provide convincing evidence in support of the view that the ascending dopaminergic systems are direct
targets for neurobiological programming by intrauterine and perinatal stress. These include maternal
exposure to restraint (psychogenic stress), hypoxia (modelling obstetric complications), immune
challenge and malnutrition (low birth weight), which alter dopaminergic activity and DA-dependent
functions in the adult offspring, such as DA release, DA transporter levels, DA-dependent learning,
locomotor activity and addictive behaviours [40,46,56–60].
Collectively, both clinical and experimental observations support the view that central developing
dopaminergic systems are highly sensitive to disruption by virtually any form of adverse environment
in utero. Prominent among themechanismswhichmay be responsible for early life programming in the
brain is exposure to elevated levels of glucocorticoids (GCs). During late gestation there is a natural rise
in the bioavailability of endogenous GC hormones (cortisol in some species such as humans, pigs and
guinea-pigs; corticosterone in other species, including rats and mice) produced by the foetal/maternal
adrenal cortex. This occurs at a critical developmental window and plays a fundamental role in the
development of mammalian tissues and organs, including surfactant production in the lungs, essential
for survival at birth, as well as processes of synaptogenesis and cell survival in the brain [61,62]. However,
exposure to these ‘normal’ late gestational elevations of GCs outside the pre-term critical window, due
to excessive/prolonged stress or therapeutic use, has proven to be deleterious, particularly in the brain.
Hence, high maternal cortisol levels in pregnancy are associated with low birth weight, sensitization
of the infant hypothalamo-pituitary-adrenal (HPA) axis response to stress, childhood behavioural
disorders and altered brain structure [44,63–68]. Investigations in animal models amply support a
mechanistic link between exposure of the developing foetus to inappropriate elevations in GCs and
programming of an altered behavioural phenotype and changes in stress-responsive and metabolic
profiles, with remarkable similarities to the clinical profiles [64,65,69–72]. The prominent sensitivity of
dopaminergic populations to developmental programming underscores the need to understand how
intrauterine elevations of GCs impact the developmental trajectories of these systems (Section 3).
2.2.3. Sex Dimorphisms
The majority of animal studies that provide evidence for neurobiological programming of
the dopaminergic systems have been performed only in males. This largely ignores the growing
awareness of innate sex dimorphisms within the SNc and VTA systems themselves, which are reviewed
elsewhere [73,74] as well as the extensive literature evidencing the qualitative as well as quantitative
nature of sex differences in the impact of early life stressors and GCs on brain structure and function in
both humans [3,9,75–78] and experimental species [74,78–85]. Clearly, this phenomenon is likely to
have considerable translational significance for brain disorders, which show a sex difference in many
respects. For example, DA-associated disorders with evidence of early-life risk factors often show a
greater prevalence in males, ranging from several-fold (autism, ADHD [35,86]) to two-fold (PD [73]).
Schizophrenia and PD also have a significantly earlier onset in males and show sex differences in
presentation, symptoms and progression [73,74,87]. Sex differences are also prevalent in all phases of
drug abuse in humans [88–90] and pre-clinical studies identify prenatal stress as a sex-specific risk
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factor for different aspects of substance abuse [84]. It is, therefore, essential that we consider the impact
of intrauterine elevations of GCs on the midbrain dopaminergic systems in both males and females.
3. Glucocorticoids and Programming of Midbrain Dopaminergic Systems
Early studies of the impact of intrauterine stress or inappropriate elevations in GCs focused on
the endocrine arm of the stress response, namely the HPA axis [64–66,72]. Although behavioural
changes could be secondary to changes in reactivity of the HPA axis, many behavioural consequences
of early life programming appear to be independent of the HPA axis [71,91]. The stress-responsive
dopaminergic circuitry is, therefore, also an important target, and here we shall specifically address the
sexually dimorphic nature of the impact of antenatal treatment with the synthetic GC, dexamethasone.
3.1. Antenatal GC Treatment (AGT)
The majority of pre-clinical investigations into the effects of AGT on the brain have administered
cortisol/corticosterone or synthetic GCs, such as dexamethasone, parenterally to the mother [92–95].
However, handling the animals and injection stress may, in itself, produce lasting effects on behaviour
and the mesencephalic dopaminergic systems in particular [96]. An effective way to combat this is to
administer GCs in the maternal drinking water [97–100]. Via this route, they are absorbed effectively,
and synthetic GCs readily cross the placenta, evading the barrier of placental 11-β hydroxysteroid
dehydrogenase, which inactivates cortisol/corticosterone and provides a degree of protection for
the fetus. In later life, the multidrug resistance protein in the blood–brain barrier regulates the
access of GCs to the brain and actively excludes dexamethasone. However, as this process is not
fully developed before birth [101], GCs in the fetal circulation will also reach the fetal brain [91,102],
where GC receptors (GRs), but not the mineralocorticoid receptors (also GC targets), are expressed
in the basal ganglia from embryonic day 15.5 in the rat [103]. The physiological relevance of the
dose of CGs administered is also a key question. In the rat, it has been estimated that the levels of
endogenous GCs required for normal lung maturation during late gestation are in the range of normal,
physiological stress levels and, from a pharmacokinetic standpoint, the optimal dose of dexamethasone
for mimicking the late gestational elevations in GCs has been estimated to be 288 µg/kg/day over
gestational days 18–20 [104,105]. Moreover, this is in the dosage range given to mothers at risk of
premature delivery (circa 0.2 mg/kg/day) in order to mature fetal lungs, with great effect on infant
survival [106–108]. Therefore, this section of the review will focus on work using a minimally intrusive
treatment protocol along with a physiologically and clinically relevant dose of dexamethasone, namely,
0.5 µg, or occasionally 1.0 µg, of dexamethasone per ml of dams’ drinking water (delivering a daily
dose of 150–175 µg/kg/day or 300–350 µg/kg/day) from gestational days 16-19 as a valid approach to
investigating the potential translational relevance of neurobiological programming by GCs [91,98,109].
3.2. Macrostructure
Notable changes in regional brain volumes (either increase or decrease) in the hippocampus,
amygdala, PFC and hypothalamus, indicative of structural changes, have been identified as a key
feature of brain disorders [1,4,5,9]. Important correlations have been made in clinical and pre-clinical
studies to suggest that, rather than being a consequence of the disorder, altered brain structural volumes
may represent a pre-existing condition, likely engendered by early life stressors, which presage an
increased risk for malfunction and vulnerability to psychopathology [3,9,110–113]. Antenatal treatment
of non-human primates with dexamethasone, as well as a prospective study of maternal cortisol levels
through human pregnancy, on changes in hippocampal and amygdala volumes, respectively, support
a key role for GCs in this structural programming, which, along with associated affective problems,
appear to be sex-specific [77,114,115]. There is, however, a paucity of information on volume/structural
changes in the VTA/SNc regions, which are relatively small, thereby presenting a particular challenge
for the resolution of in vivo volumetric data [116,117]. High resolution of small brain regions can,
however, be achieved using classical ex vivo methods to assess neuroanatomical changes [91,98,109].
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Using these methods, in conjunction with the AGT regimen described in Section 3.1, we have
characterised sex and treatment effects on the macrostructure of the SNc and VTA in the adult rats
and mice.
Dividing the nuclei into four (SNc) or three (VTA) levels relative to bregma allows for a
rostro-caudal neuroanatomical segmentation of the nuclei in rats [91,118,119] and mice (Figure 1) [109],
which enables an estimate of the shape as well the overall volume of each nucleus [91,109,118,120].
In control rats, the overall volumes were significantly greater in females than males by 46% for the SNc
and 32% for the VTA (Figure 2). Analysis of the volumes at individual levels (A–D) also revealed a
clear sex difference in the overall shape of the nuclei in the rat (Figure 2). These findings therefore add
the SNc and VTA to the growing list of brain regions where innate sex differences in their total volume
have been documented [121]. After AGT the shape of the nuclei were changed quite dramatically,
with a tendency for an increased volume caudally (males levels C, D; females level D), but a reduced
volume rostrally (females levels A and/or C). Overall, this resulted in an increase in total volume in
the male SNc and VTA, as well as the female VTA, but a small, significant reduction in the female SNc
volume. The net effect was a loss of the sex differences in nuclear shape and total volume, suggesting
that late gestational exposure to elevated GC levels feminises/demasculinises the structure of these
dopaminergic nuclei. Broadly similar effects were seen in mice, with females being generally more
sensitive to a lower dose of AGT (0.5 µg dexamethasone/mL maternal drinking water) and males
to the higher dose (1.0 µg dexamethasone/mL maternal drinking water) [109]. Using peripheral
quantitative computed tomography scanning to assess larger brain regions, we have shown that
AGT had no effect on total brain volume or relative volumes of most other brain regions, including
the striatum and amygdala, except the dorsal hippocampus, where volume was decreased [122].
These results support the view that effects reported here for the SNc and VTA are true changes in
regional volumes. Collectively, these findings support and expand the evidence that AGT has powerful,
sexually dimorphic programming effects on brain structure. Although the concept of neuroanatomical
models of disease has not previously been extended to the SNc/VTA, given current advancements in
real-time in vivo imaging [123], these findings highlight the potential for SNc/VTA volume changes
to be used as a sensitive, non-invasive biomarker for disorders where early life challenges, as well as
dopaminergic malfunction, contribute to their aetiologies.
Figure 1. Representative images, moving in a rostro-caudal direction, at the different levels of the
murine SNc (substantia nigra pars compacta) (A–D) and VTA (ventral tegmental area) (B–D). Brain
slices were processed for tyrosine hydroxylase immunoreactivity (TH-IR) and the SNc and VTA were
delineated by the TH-IR cell bodies and classical neuroanatomical landmarks. In order to detect any
regional differences in shape/volume (calculated using Cavalieri’s method [91,109] and cell distribution
through the nuclei, sections containing the nuclei were divided into four levels (A–D), each spanning
200–250 µm, beginning at the anatomical level where the SNc TH-IR cells first appear. Representative
images at each level are shown here for the mouse, with full details given in [109]. This method is
analogous to that which we have used previously for analysing the rat SNc/VTA [91].
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3.3. Microstructure
Macrostructural change indicates change in the cellular composition, and this will be discussed
below for the dopaminergic neuronal and astrocytic populations of the SNc and VTA.
3.3.1. Neurons
The SNc and VTA, classically distinguished during development as the A9 and A10 groups,
respectively, of dopaminergic neurones, represent a convenient neuroanatomical separation of these
neuronal populations. However, each region comprises functionally distinct sub-populations with
unique projections to cortical and sub-cortical structures, albeit with a complex, non-homogeneous
cellular organisation [15,24,124,125]. Thus, although no simple functional map of the midbrain
dopaminergic systems has emerged, it is abundantly clear that correct organisation or positioning of
dopaminergic neurons within the SNc and VTA, as well as their total numbers, critically affects their
function [26,124,126]. Therefore, in order to investigate the enduring effects of AGT on cytoarchitectural
organisation within the midbrain nuclei, we have adopted the rostro-caudal neuroanatomical
segmentation described in Section 3.2. Using this approach, it is possible to characterise the
cytoarchitectural arrangement within the SNc and VTA in terms of cellular numbers, distribution and
density, using tyrosine hydroxylase immunoreactivity (TH-IR) as a marker of dopaminergic neurones,
as well as autoradiographic identifications of markers of dopaminergic transmission, namely DA
receptors (D1, D2) and the DA transporter (DAT).
The small number of studies where sex has been taken into consideration suggest that there
are approximately 15% more dopaminergic neurones in the control male rat SNc compared with the
female [91,118,127], whereas, in the VTA, females possess a greater number of dopaminergic neurones
compared with males [91]. Importantly, the total numbers of dopaminergic neurones are not the only
consideration, because analyses across the rostro-caudal segmentation of the SNc and VTA of control
rats show that the percentage of dopaminergic populations are differentially distributed throughout the
nuclei in males and females, with the distribution in males being concentrated more rostrally (level A),
but more caudally in females (levels C and D) (Figure 3). Whether the innate sex differences in TH-IR
cell numbers in the murine nuclei similarly reaches statistical significance remains debatable [91,127],
but the distribution of dopaminergic neurones across the SNc and VTA of the mouse recapitulates the
innate sex differences in rostro-caudal patterning seen in rats [109].
At the dose of 0.5 µg/mL of dexamethasone in the dams’ drinkingwater, AGT significantly increased
the total numbers of TH-IR cells in the adult SNc and VTA of male and female rats [91,100,119]. This
expanded population appeared to have the characteristics of normal dopaminergic neurones [119],
as judged by their morphology, basal electrical activity and expression of Pitx3, an exclusive marker
of SN and VTA neurones required for phenotype survival and maintenance [124]. Concomitant with
increased cell numbers, TH-IR fibre density was also increased in the striatum, both in the dorsal
regions (caudate putamen) receiving their principal input from the SNc and the ventral regions (NAc
core and shell) receiving their principal input from the VTA. Although cell size was unaffected, AGT
also caused a marked redistribution of dopaminergic neurones, as characterised by a reduction in the
percentage located rostrally (level A) and an increase in the proportion located caudally (level C, D)
(Figure 4) [91,119], clearly reflecting the rostro-caudal pattern of macrostructural shift (Section 3.2).
In mice, AGT also increased TH-IR cell numbers and altered their distribution in a rostro-caudal
pattern, but, in accord with the dose-dependent effects on macrostructural changes in mice (Section 3.2),
the proportions of TH-IR neurons at each level were affected by the lower dose in females, but the
higher dose in males [109]. These studies demonstrate that there are quantitative similarities in the
effects of AGT in males and females to increase TH-IR cell numbers and also qualitative effects in that
there is a rostro-caudal shift in their distribution. However, it must be remembered that these changes
are imposed on a sexually dimorphic substrate (cell numbers and distribution in control animals),
leading to a sex-specific cytoarchitectural re-organisation.
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Figure 3. Influence of AGT on the redistribution of TH-IR (tyrosine hydroxylase immunoreactivity)
cells. The percentage of the total number of TH-IR cells located at each level throughout the SNc (A) and
VTA (B) was calculated for adult male and female rats after antenatal treatment with dexamethasone
via the maternal drinking water on embryonic days 16–19 (0.5 µg/mL,
men  with
mL, ) 
a are means ±
) compared to the control
offspring of dams receiving normal drinking water (
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(TH-IR cells) on postnatal day 2 (P2). A proportion of murine TH-IR cells undergo apoptotic changes
on postnatal day P2, as identified by immunostaining for activated caspase-3 (A), or by the presence of
nuclear condensation (B). The white arrow indicates an example of pronounced nuclear condensation.
TH-IR cell apoptosis was quantified in the combined SNc and VTA at postnatal day P2 in male and
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Investigations into factors controlling DA neurone number have largely focused on early
embryonic stages. For example, it has been established that relatively early in gestation in the rat,
around gestational day 10.5, the production of factors such as Sonic hedgehog (SSH) and FGF8 critically
determine the induction of midbrain dopaminergic neuronal progenitors, which is fundamental in
establishing the correct numbers of dopaminergic neurons in the correct position [126,128]. It would
also appear that neurogenesis, specification and migration of the midbrain dopaminergic neurons are
largely complete before the commencement of AGT [129–131]. Therefore, late gestational exposure to
GCs must be influencing already committed dopaminergic neurons to alter cell numbers and intervene
with the choreography of their stereotypic arrangement in the SNc and VTA at a relatively later
stage of gestation (embryonic days 16–18), as discussed here, and then into early postnatal stage [99].
Interestingly, the process of up-regulation of TH expression is thought to account for a sharp rise in
dopaminergic cell numbers over the last four days of gestation in the mouse [130] and their continuing
postnatal rise in the SNc to adult levels at postnatal days seven–nine [132], 14 [133] or 28 [130]. As the
TH gene contains a GC response element [134] and GRs are expressed in the rat basal ganglia by
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embryonic day 15.5 [103], it is possible that AGT could influence terminal differentiation to the DA
phenotype. Naturally occurring cell death via apoptotic mechanisms is also a process thought to play a
critical role during late gestation and the neonatal period in regulating adult numbers of dopaminergic
neurons in the SN [133,135–137]. Figure 4 shows that GC exposure on gestational days 16–19 markedly
reduced apoptotic markers selectively in the TH-IR cells of the SNc and VTA by post-natal day
two [109]. These findings accord with the ability of GCs to promote the survival of hippocampal
granule cells in the developing dentate gyrus [138,139] and suggest that AGT-mediated suppression
of the wave of ‘classical’ neuronal programmed cell death may be a mechanism contributing to the
enduring change in dopaminergic cell numbers in the adult SNc and VTA.
In terms of neurochemical parameters, autoradiographic binding densities for D1, D2 and DAT
were similar in control male and female rats in the sub-cortical and cortical regions, except for D1 in
the CPu, which in males was double that seen in females. Baseline extracellular levels of DA were also
similar in control males and females. However, in control males DA efflux in response to amphetamine,
which binds to DAT and is commonly taken as an indicator of dopaminergic tone [140], was only
25% of that seen in females (Figure 5), suggesting marked sex differences in DA terminal dynamics.
This may accord with the typically greater locomotor effects of amphetamine in females, and adds
to other evidence of inherent sex dimorphisms in the ascending dopaminergic systems [73,74]. It is
also plausible that the raised levels of D1 receptor binding in the control male CPu could counter any
apparent reductions in DA neuronal dynamics and theoretically preserve basal ganglia output, which
relies heavily on D1-mediated excitability of striatal medium spiny neurones [141].
 
Figure 5. Impact of AGT on the neurochemical response to amphetamine. Male and female rats
exposed to antenatal glucocorticoid treatment (AGT; dexamethasone, 0.5 µg/mL, in dams’ drinking
water on gestational days 16–19) and controls (dams received normal drinking water) were tested in
adulthood. Extracellular levels of DA (dopamine) in the NAc (nucleus accumbens) were assessed by
in vivo microdialysis coupled with electrochemical detection; samples were collected every 20 min.
(A) the line plots depict DA levels in each 20-min fraction for controls (pen circles) and AGT subject
(solid circles); the arrow indicates the point of amphetamine administration (0.8 mg/kg i.p.); (B) The bar
plot shows cumulative DA release above baseline (area under the curve, AUC). Values represent means
± s.e.m for control males (n = 5), AGT males (n = 6), control females (n = 4) and AGT females (n = 5)
(n values vary according to correct placement of dialysis probe and statistical analyses were adjusted
accordingly). # p < 0.05, indicating a significant sex difference; * p < 0.05 indicating a significant effect
of AGT. For full details see [119].
AGT induced marked region- and sex-specific changes in the neurochemical markers of DA
transmission (Table 1) [119]. Consistent between the sexes was an increase in binding densities for
D2 in all three sub-cortical regions (caudate puramen (CPu), NAc core and shell), but no effects were
seen in the infra-limbic cortex (ILC) and the pre-limbic cortex (PLC). D2 receptors may be located
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pre-synaptically, where they exert autoinhibitory control on DA release, or post-synaptically. While
autoradiographic data cannot distinguish between the two locations, the PFC (prefrontal cortex)
is thought to be devoid of pre-synaptic D2 receptors [142], supporting the idea that the striatal
AGT-responsive receptors are likely to be pre-synaptic. An increase in D2 auto-inhibitory control
in the striatum may, therefore, be a compensatory response which could account for the fact that
striatal extracellular levels of DA remain unaffected by AGT [119], despite the substantial increase in
dopaminergic innervation, which would be expected to lead to a hyper-dopaminergic state.
Table 1. Summary of autoradiographic analysis of changes in dopaminergic signalling proteins after
antenatal glucocorticoid treatment (AGT).
Binding
Densities
Controls Males
vs. Females
AGTMales (m) vs. Same Sex
Controls
AGT Females (f) vs. Same Sex
Controls
CPu NAc CPu
Nac
Core
Nac
Shell
ILC PLC CPu
Nac
Core
Nac
Shell
ILC PLC
D1 m > f ns ↓ ns ↓ ns ↓ ↑ ↑ ns ↑ ↑
D2 ns ns ↑ ↑ ↑ ns ns ↑ ↑ ↑ ns ns
DAT ns ns ↑ ↑ ns ns ns ↓ ↓ ↓ ↓ ↓
Foetal rats were exposed to AGT (dexamethasone 0.5 µg/mL in dams’ drinking water on gestational days
16–19). In adulthood (3 months of age) the offsprings’ brains were analysed for the expression of dopamine
receptors (D1, D2) in the striatum (caudate putamen, CPu, and nucleus accumbens, NAc, core and shell) and the
pre-frontal cortex (infralimbic cortex, ILC, and pre-limbic cortex, PLC). ↓ and ↑ represents significant decreases
or increases, respectively, for the effects of AGT relative to same sex controls; ns indicated no significant effect.
Male/female comparisons showed significant sex differences for D1 and DAT (dopaminergic transmission)
binding across all regions after AGT. Full details and data can be found in [119].
Unlike effects on D2 receptors, AGT had diametrically opposite effects on D1 receptors in male
and female rats, substantially reducing binding densities in males (CPu, NAc shell and PLC), but
increasing them in females (CPu, NAc core, ILC and PLC). Interestingly, amphetamine-induced DA
efflux was enhanced four-fold in AGT-males, but was reduced in AGT-females, raising the possibility
that the respective, co-incident up-regulation and down-regulation of post-synaptic D1 receptors may
represent compensatory changes to preserve DA transmission. In parallel with this, AGT increased
DAT level in males (CPu, NAc core), but decreased them in females (CPu, NAc core and shell, ILC,
PLC), which would also be in accord with sex differences in the direction of AGT-induced changes
in sensitivity to amphetamine (Figure 5). As a pre-synaptic marker, the DAT protein has also has
been used as an indicator of terminal density. Accordingly, an increase in striatal DAT binding in
AGT-males is in line with the AGT-induced TH-IR terminal density. However, this argument does not
hold true in females, where DAT density is reduced after AGT, despite an increase of ~40% in TH-IR
terminal density. This apparent discrepancy may simply reflect the importance of DAT in adapting to
prevailing conditions, and cautions against its sole use as an indicator of terminal density. Additionally,
counter-regulatory influences from the PFC should also be considered.
The mesocortical DA system interacts with pyramidal and non-pyramidal cortical neurons
expressing D1 and D2 receptors [143] and exerts powerful inhibitory control over the mesolimbic
DA system [144,145]. As summarised in Table 1, in male progeny, AGT had no influence on synaptic
markers of DA transmission (D1, D2, DAT) in the IL cortex [9], which projects to the NAc shell [146,147],
whereas D1 levels in the PL cortex (projecting to NAc core) were strongly reduced. This suggests
a loss of mesocortical inhibitory control of the mesolimbic system after AGT, which accords with
the enhanced mesolimbic activity revealed by amphetamine-induced DA efflux in AGT-exposed
males. Conversely, in AGT-exposed female progeny, a dramatic increase in PL and IL D1 levels
and a precipitous fall in DAT to almost negligible levels [119] could indicate an increased inhibitory
drive from the PFC, compatible with reduced mesolimbic DA activity revealed by amphetamine
administration. These data demonstrate that mesocortical as well as mesolimbic DA networks are
differentially influenced by AGT in males and females. As corticostriatal axons can facilitate DA
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release at terminal level without affecting DA impulse activity in the VTA [148], altered mesocortical
DA activity could explain why AGT altered intrinsic mesolimbic DA activity without affecting the
neurophysiology of VTA neurons in adult rats [119].
3.3.2. Astrocytes
Astrocytes are the main glial cell type in the brain and, far from the original view that they are the
inert packing material providing physical support for neurons (the cell types often regarded as the
principal functional entities in the brain), we now know that astrocytes play critical roles in normal
brain development, structure and function as well as pathologies [149–151]. However, the contribution
of this cell type to neurobiological programming in the brain has been largely ignored, but studies
in mice [109] and rats [152] have demonstrated profound effects of AGT on the number, density
and distribution of astrocytes in the SNc and VTA, depending on dose, sex and sub-region of the
SNc/VTA. In control animals, the total number of cells expressing immunoreactivity for glutamine
synthetase (GS-IR), the astrocytic marker ([150,153], and their distribution across the nuclei were
similar in males and females, except for the near negligible numbers at the midpoint of the female
VTA (level C, Figure 6). At a dexamethasone dose of 0.5 µg/mL in the dams’ drinking water, AGT
produced a dramatic two–three-fold increase in the estimated total numbers of GS-IR cells of the adult
SNc and VTA of both sexes (greater in females than males), with effects at most levels, depending
on sex. Perhaps surprisingly, this was not accompanied by any volume changes, thereby leading to
a marked two–four-fold increase in cell density at all levels throughout both nuclei, except for the
female VTA at level C, where density increased seven-fold. This reveals that cellular changes can
occur without structural changes, highlighting that structural changes alone may not be sufficient as
potential indicators of deficits in function, which would also require markers of functional and/or
biochemical change. Using a higher dose of AGT (1.0 µg/mL), GS-IR cells appeared largely unaffected
in AGT-females. A broader dose–response curve would be needed to investigate further, but this may
well reflect a bell-shaped curve typically seen for the actions of GCs. In contrast, in males, astrocyte
counts were similarly raised after both the high and low doses, but unlike the low dose, the higher dose
led to an expansion of regional volumes, resulting in no effect on astrocyte density. Further studies
measuring astrocyte size would be invaluable in interpreting these findings, but this is a complex
matter. It is not clear what factors regulate astrocyte size, but this is crucial to their function as each
astrocyte occupies a large, unique spatial domain associating with several hundred dendrites and
100,000 synapses in the rodent brain, and 20-fold more synapses in the human brain [154]. Although
GS-IR is very effective for visualising the immediate astrocyte cell body, making it ideal for cell counting
purposes, it provides little information on astrocyte size, which is a very dynamic entity. Another
commonly used astrocytic marker, glial fibrillary acidic protein (GFAP), detects an astrocyte-specific
cytoskeletal protein, but this marker also has its limitations in that it has been estimated that it reveals
approximately only 15% of total astrocytic volume [150,154]. Whatever the precise effects of AGT are
on astrocyte structure and their overall contribution to the altered volume and shape of the adult SNc
and VTA, it is clear that AGT alters the astrocytic environment in which the dopaminergic neurons
function in a sexually dimorphic manner. This suggests a further mechanism which may underpin the
sex-specific effects of early environmental disturbances on adult behaviours, and supports the view
that astrocytic disruptions contribute to DA-dependent CNS pathologies which exhibit sex differences
as well as a developmental component, including schizophrenia, depression and neurodegenerative
disorders [149–151].
The effect of AGT at a dexamethasone dose of 0.5 µg/mL in the dams’ drinking water to increase
astrocyte cell density was manifest by P2 in both sexes [119]. As most astrocytes are produced
post-natally [155] and cessation of AGT at day 19 of a 21 day gestation period ensures that the mice
are dexamethasone-free at birth, it follows that postnatal astrocyte development is highly sensitive to
prenatal events, the course of which can be altered by AGT. Neural precursor cells in the developing
vertebrate CNS first form neurons and then undergo a “neurogenic-to-gliogenic switch” late in
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gestation [154], but the triggers for this switch are unclear. Notably, GRs are expressed in astrocytes,
GCs can up-regulate GS, and maturation of the adrenal gland, with the associated rise in GC levels, has
been linked to glial differentiation, at least in the chick retina [153,156]. The sensitivity of the SNc/VTA
astrocytes to AGT further indicates an important role for GCs in astrocyte ontogeny and invites the
intriguing speculation that GCs have a role in regulating neural precursor cell fate.
 
Figure 6. Estimated astrocyte counts in control rats. The distribution of astroi re 6. sti ated t t c tr l rats. The istri tion cytes (GS-IR,
immunoreactivity for glutamine synthetase) across the adult SNc (A,B) and VTA (C,D) and estimated
total astrocyte counts are presented for male (A,C) and female (B,D) mice. + p < 0.05 for male vs.
female. For fill details see [109].
3.3.3. Behaviour
As reviewed elsewhere [58], there are many inconsistencies in the findings from behavioural
studies regarding the responses of the mesocorticolimbic and nigrostriatal dopaminergic systems to
intrauterine stressors, with outcomes that may be detrimental, advantageous or without effect, and it
is often assumed, but not proven, that exposure to maternal GCs effects the change [157]. The reasons
for these inconsistencies will be due inevitably to many variations in experimental design [9], which
are likely to present different challenges and elicit unique responses from the dopaminergic systems.
The considerable variation in the nature, intensity and duration of the chosen stressors is one key
factor and, although cortisol release will be a common response, each stressor may also challenge
other systems in the body, affecting, for example, immune, metabolic and cardiovascular responses,
adding their unique influences to those of the HPA axis. Outcomes will also depend on the degree of
maturity of the neural substrate at the point of exposure to the challenge as well as the age and sex
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of the progeny when behavioural tests are performed [9,68,70,71,83,158,159]. Here, we shall focus on
the consequences of AGT given during late gestation on performance in behavioural tests known to
depend on midbrain dopaminergic circuitry, which has relevance for GC use in perinatal medicine,
as well as some bearing on late gestational stressors.
Taken individually, one could reasonably predict behavioural disruption by AGT on the basis
of the substantial neurobiological changes that are seen in DA cell counts, striatal fibre density, DA
receptor and DAT levels, and DA release (Sections 3.2, 3.3.1 and 3.3.2). Accordingly, when rats were
placed in a novel environment, spontaneous open-field locomotor activity was attenuated in female
progeny after AGT (Figure 7A,B), indicating suppression of motivational arousal, which depends
on DA release within the mesolimbic and nigrostriatal DA systems [160]. In contrast, males were
unaffected in this test (Figure 7A,B). Interestingly, these effects are compatible with the co-incident,
sexually dimorphic neurobiological changes, which indicated a reduction in intrinsic mesolimbic
dopaminergic activity in AGT-females, whereas in AGT-males the increase in activity may be offset by
an increase in DAT and a reduction in D1 receptors in the striatum [119]. Using a completely different
challenge of intrauterine anoxia stress, male rats showed an increase in spontaneous locomotor activity
(a hyper-activity of the mesolimbic-NAc system), which was attributable to a loss of inhibitory control
from the medial PFC, possibly due to an increase in DAT, but with no effect on D1 and D2 receptors
in the PFC [40]. These contrasting outcomes stress the susceptibility of the dopaminergic systems to
neurobiological programming and also serve as a clear illustration of the great variability in outcomes,
depending on the nature of the challenge. In male rats, a startle stimulus has been shown to lead to a fall
in NAc DA levels, but if a weak pre-pulse is presented prior to the startle stimulus, the fall in NAc DA is
attenuated [161]. In contrast to the effects of AGT on spontaneous open-field activity, the performance
of AGT-females was unaffected in this test of pre-pulse inhibition (PPI; Figure 7D), whereas in males
PPI was exaggerated (Figure 7C), which would be compatible with greater response to amphetamine
in AGT-males (Section 3.3.1, Figure 5) [119]. Surprisingly, however, in other established tests of
mesolimbic activity, including amphetamine-induced locomotor activity, cocaine self-administration
and learning in response to appetitive cues predictive of food [160,162–165], neither males nor females
were affected by AGT [119]. We conclude, therefore, that apparent behavioural normality in some,
although not all, circumstances is achieved by powerful, AGT-induced compensatory mechanisms,
which preserve DA transmission via different, even opponent, processes in males and females
(as indicated by the sexually dimorphic neurobiological changes consequent on AGT). Our recent study
shows that compensatory mechanisms also operate within the mesocortical dopaminergic system.
Thus, we found that AGT dramatically protects male rats from the disruptive effects of a D1 receptor
agonist on a test of spatial working memory, a cognitive function that depends on the functional
integrity of DA inputs to the mPFC [166].
It must be noted, however, that some studies involving late gestational GC treatment, have
reported significant behavioural effects in both sexes, especially in tests of anxiety and depression-like
behaviours [70,93–95]. However, most studies include the additional stress of parenteral administration
of GCs during gestation, and often high doses of dexamethasone, several-fold greater than that used
in perinatal medicine, are administered [93,95]. Additionally, the tests of anxiety and depressive-like
behaviours, such as the forced swim tests or the elevated plus maze, encompass stress exposure
in adulthood [93,95]. This contrasts with the behavioural tests described in Virdee et al. [119],
where the aim was to investigate animals under basal conditions, reflecting intrinsic functional
connectivity [167]. Such differences are likely to have important consequences for behaviour, because
apparently protective adaptations that allow behaviours to appear normal under basal conditions, may
fail when confronted with challenges later in life. In support of this, human and non-human primate
studies reveal abnormalities in the HPA response to stressors in adult life in individuals exposed
to early adversity [168,169] and the central dopaminergic response to stress in adult guinea-pigs
and rats is altered in animals exposed to birth insults [170]. Furthermore, mesolimbic dopamine
release in response to a psychosocial stressor in human adults is sensitive to the effects of early life
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events [75]. Collectively, these observations suggest that, although the adaptive operational changes in
the midbrain dopaminergic systems are protective within certain limits, this is at the cost of the network
operating outside its normal limits, a state termed allostasis, or ‘stability through change’ [171,172],
so that an apparent resilience to early adversity could, ultimately, become a pre-disposing factor
to (psycho)pathology.
 
Figure 7. Behavioural impact of AGT. Male and female rats exposed to antenatal glucocorticoidFigure 7. Behavioural impact of AGT. ale and fe ale rats exposed to a tenatal l cocorticoid
treatment (AGT; dexamethasone, 0.5 µg/mL, in drinking water on gestational days 16–19; solid
circles/bars) and controls (dams received normal drinking water; open circles/bars) were tested in
adulthood. (A,B) Spontaneous locomotor activity is suppressed in adult female, but not male, progeny
after AGT. Data are mean ± s.e.m., n = 6; * p < 0.05 for AGT vs. control group; # main effect of
sex, p = 0.001. (C,D) The paradigm of prepulse inhibition of the startle response (PPI) was used to
investigate sensorimotor gating in young adult offspring. This is significantly modulated after exposure
to AGT in adult male (C), not female (D), progeny. Data are mean ± s.e.m., n = 8; * p < 0.05 for AGT vs.
vehicle. For full details see [119].
3.4. Why Should the Influences of AGT Be Sexually Dimorphic?
Some subtle differences in the rates of maturation of male and female foetuses may have
implications for sex-specific programming influences [76], but most research attention has focused
on genetic and hormonal influences. By late gestation, male and female embryos have experienced
a substantially different genetic and hormonal milieu, which is critically responsible for survival of
the species. This underpins sex differentiation not only of the male and female reproductive tracts,
but also of hypothalamic circuitry controlling ovulation in females as well as unique reproductive
behaviours that characterise females and males [73,74,85,173–176]. At conception, the embryo is
sex neutral, but after a few days’ gestation in rats and mice, or around six weeks’ gestation in
humans, expression of genes on the male Y chromosome initiate processes of masculinisation and
defeminisation. Specifically, activation of the sex-determining region of the Y chromosome (SRY) gene
directs development of male genitalia, and activation of the anti-mullerian hormone (AMH) gene
blocks the formation of female genitalia. The associated early gestational wave of testicular testosterone
production stimulates maturation of the male gonads. A later wave of testosterone production occurs
in the rat at embryonic days 17–19 and immediately after birth [177,178] or around mid-gestation in
humans [179]. This is a critical window for brain development, when masculinisation/defeminisation
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of the male hypothalamus occurs, without which this circuitry would proceed largely along female
lines by default. However, testosterone readily crosses the blood–brain barrier to reach all brain regions,
where it has the potential to permanently modulate neurite extension, synaptogenesis, cell survival and
apoptosis. Hence, growing evidence suggests that many other brain regions, such as the hippocampus,
amygdala and cortex, which are involved in memory, learning, cognition, emotion and stress reactivity,
are subject to such hormonal sex differentiation at critical windows of development [9,85,175,180–183].
Raised GC levels and intrauterine stressors are, therefore, acting on a significantly different substrate
in male and female brains, providing a framework to explain the sexually dimorphic consequences of
AGT. In support of this, perinatal stressors and elevated GCs can interfere with normal masculinisation
of the hypothalamus and male sexual behaviour [177,184–186], and our findings that AGT can feminise
the structure, shape and cytoarchitectural arrangement within the SNc and VTA, would support and
extend this concept to other brain regions.
However, direct evidence is required to confirm that the innate sex differences seen in the
structure and function of the SNc and VTA (Sections 3.2, 3.3.1 and 3.3.2 [73,74]) are indeed, hormonally
programmed during the classical period for brain sexual differentiation. Using the classical hormonal
manipulations of gonadectomy of newborn male rats and testosterone treatment of newborn females
in order to achieve, respectively, the removal or addition of the masculinising/defeminising influences
of testosterone [187], we have attempted to provide this evidence for the organisational (irreversible)
effects of sex hormones on the SNc and VTA systems. In view of the sensitivity of these systems to
neurobiological programming, it is, perhaps, not surprising that we found that the sham-operated
and vehicle-injected control animals showed marked changes in TH-IR cell numbers in the VTA
and SNc, making the data uninterpretable (unpublished observations). In the absence of such
confirmatory data, one should consider a role for the activational (reversible) influences of the
adult sex hormone environment. Studies in gonadectomised rats have shown that estradiol in
females enhances dopaminergic transmission, whereas neither estradiol nor testosterone has any
influence in males [188–191]. Therefore, as responses are clearly still sexually-differentiated when the
influences of sex hormones are removed and equalised in males and females, it follows that there
remains a significant sex difference in the underlying circuitry. Moreover, sex hormone manipulations
in adulthood do not affect TH-IR cell number, the prevailing differences in the adult hormonal
environment cannot account for sex differences in cell numbers [118,192,193]. Together with the
sexually dimorphic responses of the midbrain systems to environmental disturbances in utero already
discussed, these findings constitute strong indirect evidence in support of a role for hormonal-mediated
organisation of these sex differences.
Although sex hormones are considered to be the primary factors for driving structural and
functional sex differentiation of the brain, there is evidence to suggest that genetic, cell-autonomous
factors also make a contribution. For example, investigations using sex-specific mesencephalic
cultures derived from embryonic day 13, a time-point presumed to precede the late gestational rise in
testosterone, reported the emergence of sex-specific characteristics in terms of TH-IR cell numbers,
DA levels and DAT activity in rats and some, but not all, strains of mice, suggesting an influence of
genetic background [194]. Evidence in humans and other species suggest that the sex chromosomes
themselves are likely contributors to such sex differences [195], especially the SRY gene. Although the
actions of this gene were classically thought to be restricted to sex determination early in gestation,
its expression has now been identified through development and into adulthood in a number of male
non-reproductive tissues, including the brain in humans, rats and mice [127,196,197]. Moreover, SRY
expression co-localises with a subset of dopaminergic neurones of the SNc in adult rodent and human
post-mortem brains [127,198] and may contribute not only to the sex differences seen in dopaminergic
cell numbers, but also the greater male susceptibility to PD [199]. Whether a similar impact of SRY
occurs in the VTA dopaminergic populations remains to be discovered. Clearly, future studies are
needed to determine how sex-specific genes, as well as hormonal factors, differentially alter interactions
of DA populations with the early environment and susceptibility to later disease in males and females.
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4. Summary
Neuroanatomical and neurochemical parameters clearly demonstrate that intrauterine exposure
to inappropriately raised levels of GCs has profound effects on the normal developmental trajectories
of the midbrain dopaminergic systems, leading to enduring changes in the cytoarchitecture (neurons
and glia) and activity of the mesocorticolimbic and nigrostriatal dopaminergic systems. Moreover,
the changes in these parameters are often qualitatively diametrically opposite in males and
females. Remarkably, these robust, sexually dimorphic changes were not accompanied in either
sex by altered psychomotor and appetitive behaviours that are known to depend on midbrain
dopaminergic transmission. We propose, therefore, that such neurobiological changes represent a broad
spectrum of enduring adaptive mechanisms, which underpin apparent behavioural resilience to early
environmental perturbations, but these proceed via very different mechanisms in males and females.
However, such adaptations appear not to be completely protective. For example, certain DA-dependent
behaviours can be affected by AGT in females, but not males (locomotor response to novelty), whereas
others are affected in males, but not females (sensorimotor gating). Hence, AGT-induced permanent
adaptions in dopaminergic circuitry proceed via different, often opponent, mechanisms in males
and females. This establishes an important principle of neurobiological programming that is likely
to hold for all types of early-life challenges affecting all brain systems, whether dopaminergic or
not [82,200]. Although a rather neglected area, recent evidence also suggests a key role for glial cells in
the sex-specific process of biological programming, which merits closer investigation.
Whatever the underlying processes, AGT programming of the midbrain dopaminergic systems
has significance for the use of GCs in perinatal medicine. In around 10% of pregnancies worldwide,
women are given AGT to promote foetal lung maturation and infant survival in cases of threatened
premature delivery. A single course of AGT has unquestionable value, with little evidence for
deleterious effects [107]. However, repeated courses, which have been given routinely to women
who remain undelivered (50% of cases), are linked to long-term, potentially deleterious effects on the
developing brain [201–203]. These include decreased bodyweight, head circumference and brain
volume at birth [204], altered stress responses in infants [66,205] and altered behaviours, such
as hyperactivity and distractibility [10], which have been linked to alterations in dopaminergic
signalling [12]. Due to the complex and varied nature of stressors, it would be unwise to suggest that
the outcomes discussed here for AGT-induced programming of the brain would be identical to those
incurred after intrauterine exposure to stress. However, human studies have made direct links between
stress-induced elevations in maternal cortisol levels outside the critical, late-gestational window when
levels normally rise, and sexually dimorphic effects in the brain. These include sex-specific changes
in regional brain volumes and HPA axis reactivity, as well as compromised aspects of cognition and
affective behaviour in childhood [63,115,206,207]. Systematic investigations into the potential impact
of GCs on the developing brain and neurological and behavioural outcomes are, therefore, key to
ensuring their safe use clinically.
In summary, the evidence presented here has identified sexually dimorphic capacities for
molecular adaptations within the midbrain dopaminergic systems in response to AGT, which may
confer sex-specific behavioural resilience or vulnerability to early-life environmental challenge,
depending on the specific behaviour tested. Moreover, the sex dimorphisms may have translational
relevance for DA-dependent psychopathologies that show a sex bias as well as a susceptibility to
early environmental challenge [208]. For example, we have identified an effect of AGT on female,
but not male, behaviours (motivational arousal), which have correlates with behaviours that are
altered in depression, a condition generally more prevalent in women [209]. Equally, we have
highlighted male behaviours (pre-attentional processing/PPI), which are affected in male, but not
female, schizophrenics [210]. Notable sex differences in the capacity to adapt to early life challenges
may, therefore, underpin the notable sex bias in DA-dependent psychopathologies, and highlights the
need for a greater understanding of the underlying processes if we are to improve treatments, which
need to be tailored to the specific needs of men and women. A key challenge for the future will be
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the elucidation of mechanisms that underpin the sexually dimorphic responses to AGT. Epigenetic
programming is emerging as a critical factor in brain sexual differentiation, which is driven, to a large
extent, by a surge in testosterone production by the testes, occurring between GD17 and postnatal
day 10 in the male rat [211,212]. Prenatal synthetic GC treatment can also permanently modify the
epigenome [213], and produce endocrine and behavioural effects which may be qualitatively and
quantitatively different in males and females [12,65,81]. Differential interactions of glucocorticoids
with the sex-specific gonadal steroid environment at the level of epigenetic markers in the developing
male and female brain provides a platform for sexually dimorphic outcomes [214]. Whether the
midbrain DA systems are targets for such actions remains to be determined, but this would offer a
compelling explanation for their sexually dimorphic programming by AGT.
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